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melanomas exact a disproportionate toll.
The data from these analyses provide
strong grounds for enacting policies of
melanoma education, primary prevention
and close surveillance for all patients
undergoing organ transplantation.
Suspicious pigmented lesions should be
managed promptly in all such patients. For
OTRs diagnosed with melanoma, referral
to expert centers would seem prudent.
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CYR61/CCN1: A Novel Mediator of
Epidermal Hyperplasia and
Inﬂammation in Psoriasis?
Taihao Quan1, Andrew Johnston1, Johann E. Gudjonsson1 and
Gary J. Fisher1
The complex pathogenesis of psoriasis is still not fully understood. The study by
Sun et al. (2015) suggests that CYR61 (now named CCN1), a secreted
matricellular protein, has a role in the pathogenesis of psoriasis, and thus
targeting CCN1 represents a potential therapeutic strategy in its treatment.
Journal of Investigative Dermatology (2015) 135, 2562–2564. doi:10.1038/jid.2015.300
CCN1 in psoriasis: new ﬁndings and
clinical implications
Psoriasis is a chronic inﬂammatory skin
disease characterized by hyperprolifera-
tion of epidermal keratinocytes and result-
ing in scaly, red, and well-demarcated
skin lesions. Hyperproliferation is driven
by the additive and synergistic activities of
a plethora of cytokines and growth factors
(Baliwag et al., 2015) acting on and
driving changes in the architecture of
the epidermis, keratinocytes, resident and
inﬁltrating immune cells, as well as
ﬁbroblasts and vascular endothelium in
the dermis (Elder et al., 2010). In this
issue, Sun et al., (2015) add another
ingredient to the inﬂammatory recipe
responsible for driving this disease;
they report that the expression of CCN1,
a multifunctional non-structural protein
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found in the extracellular matrix (ECM), is
elevated in the skin of patients with
psoriasis, as well as in psoriasis-like
mouse models. Importantly, blocking
CCN1 function by either lentiviral-based
sh-RNA knockdown of CCN1 or anti-
CCN1 neutralizing antibodies attenuated
the epidermal hyperplasia and inﬂamma-
tion seen in the psoriasis-like mouse
models. Thus, they concluded that
CCN1 participates in the pathogenesis of
psoriasis and that targeting CCN1 could
be an important therapeutic strategy.
Although the mechanisms by which
CCN1 promotes epidermal hyperplasia
and inﬂammation are not fully under-
stood, Sun et al., (2015) present ﬁndings
that CCN1 acts through integrin α6β1 on
keratinocytes. This interaction activates
downstream PI3K/Akt/NF-κB signaling
pathways. This ﬁnding has clinical
implication by suggesting α6β1 integrin
as a relevant target.
CCN1 is a secreted protein that
interacts with the ECM, making it a
member of a large family of matricel-
lular proteins. On the basis of structural
homology, CCN proteins comprise a
family of six members, CCN1-6 (Perbal,
2004). The CCN acronym is taken from
the names of the ﬁrst three members
of the family to be discovered: CYR61/
CCN1 (cysteine-rich protein 61), CTGF/
CCN2 (connective tissue growth factor),
and NOV/CCN3 (nephroblastoma
overexpressed gene). Members of the
CCN family exhibit diverse cellular
functions, such as regulation of cell
proliferation, chemotaxis, apoptosis,
adhesion, motility, ion transport, and
ECM regulation (Chen and Lau, 2009).
CCN1 has been reported to regulate
cell adhesion, migration, chemotaxis,
inﬂammation, cell–matrix interactions,
synthesis of ECM proteins, and wound
healing in a variety of cells in culture (Jun
and Lau, 2010; Lau, 2011). CCN1 exerts
this range of functions through
interaction with multiple integrins in a
cell-type and context-dependent manner
(Figure 1) (Lau, 2011). During embryonic
development, CCN1 has a critical
role in vascular development and blood
vessel formation in the placenta. CCN1
knockout in mice is embryonic lethal
primarily due to a failure in vascular
development caused by impaired
ECM homeostasis. Studies in animal
models and in patients have conﬁrmed
that deregulation of CCN1 protein is
found in several diseases associated
with chronic inﬂammation and/or tissue
injury, including rheumatoid arthritis,
atherosclerosis, diabetes-related
nephropathy and retinopathy, and many
forms of cancer (Chen and Lau, 2009;
Kular et al., 2011).
What drives sustained elevation of CCN1
in psoriatic skin?
The study by Sun et al. (2015) reveals
elevated CCN1 in the skin of patients
with psoriasis and its potential role as a
driving force for epidermal hyper-
plasia and inﬂammation. Obviously,
their ﬁndings raise the question of what
drives the sustained elevation of CCN.
Several recent studies have shown that
the CCN1 expression is regulated directly
by the transcriptional co-activator Yes-
associated protein (YAP), a major down-
stream effector of the hippo signaling
pathway. In mouse skin, YAP has a
critical role in regulating keratinocyte
proliferation, differentiation, and survival
through upregulation of CCN1 (Zhang
et al., 2011). In the human skin cancer,
basal cell carcinoma, YAP, and its
downstream transcriptional target CCN1
are elevated markedly in tumor islands.
In human keratinocytes, knockdown of
YAP signiﬁcantly reduces the expression
of CCN1 and represses proliferation and
survival. This inhibition of proliferation
and survival is rescued by restoration of
CCN1 expression (Quan et al., 2014).
These data provide evidence that up-
regulation of YAP promotes aberrant
keratinocyte proliferation through up-
regulation of CCN1 in basal cell
carcinoma. Although the expression of
YAP in psoriasis is unknown, these data
suggest that YAP may be involved in
upregulating CCN1 in psoriasis.
The study by Sun et al.
(2015) suggests that
CCN1, a secreted
matricellular protein,
has a role in the
pathogenesis of
psoriasis, and thus
targeting CCN1 may
represent a potential
new therapeutic strategy
in psoriasis treatment.
In addition, a positive feedback loop
between CCN1 and the cytokine
network may also contribute to the
sustained elevation of CCN1 in pso-
riatic skin. CCN1 not only promotes the
production of cytokines (Qin et al.,
2014), it is also induced by cytokines,
growth factors, and environmental
stressors (Chen and Lau, 2009),
suggesting that a positive feedback
loop may contribute to sustained
elevation of CCN1 found in psoriatic
skin. Therefore, targeting CCN1 could
be an effective therapeutic strategy by
inhibiting such a positive feedback loop
in psoriasis.
Important role of CCN1 in skin biology
CCN1 could be an important regulator
in skin biology, as it impacts both
epidermal keratinocytes and dermal
ﬁbroblasts. In normal adult human
skin, CCN1 is substantially elevated in
Clinical Implications
● CCN1 is a potential new ingredient in the recipe of inﬂammatory
mediators that drive psoriasis.
● Targeting the interaction of CCN1 with integrin α6β1 represents a
potential new strategy to treat psoriasis.
● CCN1 may function as an important regulator in skin biology, by
modulating key functions of keratinocytes and ﬁbroblasts.
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the dermis by aging, as well as under
the inﬂuence of ultraviolet irradiation
(Quan and Fisher, 2014). Elevated
expression of CYR61/CCN1 in the
dermis leads to reduced collagen
production by impairing TGF-β signal-
ing (Quan and Fisher, 2014) and
increasing collagen ﬁbril fragmentation
through the production of multiple
matrix metalloproteinase proteins
(MMPs) (Quan and Fisher, 2014).
Thus, elevated CCN1 promotes skin
thinning and fragility, two prominent
features of aged skin, but interestingly
this is not seen in long-standing psor-
iasis suggesting the involvement of
other mitigating factors as well.
Abnormal regulation of CCN1 expres-
sion has been observed in several skin
diseases, including wound healing and
ﬁbrosis (Jun and Lau, 2010). Studies in a
mouse model have demonstrated that
CCN1 exerts anti-ﬁbrotic activity via
induction of dermal ﬁbroblast senescence
during cutaneous wound healing. Elevated
CCN1 may also have a signiﬁcant impact
on the delayed wound healing seen in
elderly patients. CO2 laser ablation, which
causes partial thickness wounding, rapidly
and markedly induces CCN1 in human
skin dermis in vivo (Quan and Fisher,
2014). Timing of the elevated CCN1 levels
corresponds to the inﬂammatory phase
(ECM breakdown), and the timing of
CYR61/CCN1 diminution corresponds to
the ECM remodeling phase (collagen
production) of wound healing responses.
Also of note, CCN1-regulated factors
such as proinﬂammatory cytokine (IL-1β),
collagen-degrading MMPs (MMP-1,
MMP-3, and MMP-9), and type I procolla-
gen are well-known components of the
wound healing response. These data
suggest that CCN1 may have a critical
role in regulating wound repair in human
skin. Further support comes from mouse
studies, which have reported that CCN1
is induced by cutaneous wounding and
that it participates in both the inﬂam-
matory and remodeling phases of repair
(Jun and Lau, 2010). Therefore, the
constitutive elevation of CCN1 in aged
human skin may delay wound healing by
extending the inﬂammatory phase and
delaying the remodeling phase. These
ﬁndings highlight CCN1 as a possible
therapeutic target, not only for psoriasis
but also for improving wound healing in
the elderly and in skin cancer.
Concluding remarks
The results reported by Sun et al. (2015) in
this issue reveal the potential role of
CCN1 in the pathogenesis of psoriasis.
This study, together with other emerging
data, suggests that CCN1 may function as
an important regulator in skin biology, by
modulating key functions of keratinocytes
and ﬁbroblasts. Clearly, there remains
much to be learned about the regulation
of CCN1 and its functions in skin
physiology and pathology. It should be
noted that CCN1 is one of the six
members of the CCN family. CCN2 is a
well-established mediator of ﬁbrosis.
However, little is known regarding
the roles of CCN3-6 in skin biology.
Certainly the article by Sun et al.
(2015) should spur new appreciation
of the importance of the CCN family of
proteins in skin biology.
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Figure 1. Full-length CCN1 contains 381 amino acids with an N-terminal signal peptide followed by four
structurally distinct domains (Lau, 2011; Perbal, 2004): an insulin-like growth factor binding protein
(IGFBP) domain, a von Willebrand type C repeats (vWC) domain, a thrombospondin type 1 repeat (TSR)
domain, and a C-terminal (CT) cysteine-knot motif domain. CCN family proteins have an unusually high
cysteine content (~10% of residues), and the number and spacing of these cysteine residues are fully
conserved in CYR61/CCN1, CTGF/CCN2, NOV/CCN3, and WISP1/CCN4, whereas being largely
conserved in WISP2/CCN5, which lacks the CT domain, and WISP3/CCN6, which lacks 4 cysteine
residues in the vWC domain. CCN1 promotes diverse and sometimes opposing cellular responses, which
can be assigned, as least in part, to disparate activities mediated through distinct integrins expressed by
different cell types. Accordingly, CCN1 promotes cell proliferation, survival, and angiogenesis by binding
to αvβ3 integrin, and it induces apoptosis and senescence through α6β1 integrin and heparan sulfate
proteoglycans (HSPGs).
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